Metformin’s mechanism of action through the AMPK pathway and its effects on the mTOR/S6K1 axis suggest comprehensive anti-tumoral activity, from reducing cell viability to modifying the tumor’s edema and microenvironment. Here, RPS6KB1 is linked to neoplasm.